Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23295688 | 1.00 | ITGB3 (0.46) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL6254584 | 0.82 | NPPA (0.54) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL30801969 | 0.79 | ITGB3 (0.51) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL25428196 | 0.79 | MME (0.36) | ACE | |
| SCHEMBL23295427 | 0.79 | MME (0.36) | ACE | |
| SCHEMBL25277595 | 0.79 | ITGB3 (0.51) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL10292465 | 0.78 | ACE (0.50) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL15248138 | 0.77 | HTT (0.41) | — | |
| SCHEMBL23295526 | 0.76 | ITGB3 (0.48) | ITGB3ITGA2BACECTSSCTSK | |
| SCHEMBL2002586 | 0.76 | CTSS (0.50) | ITGB3ITGA2BACECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12384750-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-11952352-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4054719-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042740-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ITGB3 1924/4885ITGA2B 2903/4885ACE 1904/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | ITGB3 4509/4885ITGA2B 4143/4885ACE 2741/4885 |
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ITGB3 3155/4885ITGA2B 3247/4885ACE 766/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ITGB3 3155/4885ITGA2B 3247/4885ACE 766/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ITGB3 2895/4885ITGA2B 3131/4885ACE 1617/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ITGB3 3155/4885ITGA2B 3247/4885ACE 766/4885 |
| US-12384750-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ITGB3 3155/4885ITGA2B 3247/4885ACE 766/4885 |
| US-11952352-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ITGB3 3155/4885ITGA2B 3247/4885ACE 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.